Equity Overview
Price & Market Data
Price: $0.334
Daily Change: -$0.0136 / 4.07%
Daily Range: $0.323 - $0.414
Market Cap: $31,017,992
Daily Volume: 1,204,103
Performance Metrics
1 Week: 14.86%
1 Month: -6.18%
3 Months: -22.33%
6 Months: 12.04%
1 Year: -13.29%
YTD: -0.60%
Company Details
Employees: 70
Sector: Health technology
Industry: Biotechnology
Country:
Details
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatment of metabolic disorders and Alzheimer's disease; and IGC-1A to treat metabolic disorders. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.